TY - JOUR
T1 - The benefits of active compounds in Kalanchoe Pinnata (LMK) pers ethyl acetate fraction on lupus arthritis mice
AU - Indriyanti, Niken
AU - Soeroso, Joewono
AU - Khotib, Junaidi
N1 - Funding Information:
?his research was funded by DIPA PNBP 球爃猃眀 Faculty of Pharmacy Universitas ?ulawarman (Grant number: 猃礃稃礂?UN 猃礁猃琂?HK/ 球爃猃眂I; Hibah Penelitian Disertasi Doktor 球爃猃礀 from ?inistry of Higher Education, Indonesia (Grant number: 爃球眂?E 甁瘂 球爃猃礂I, and DIPA-PNBP FF Unmul funding for 球爃猃礀 (Grant number 爃礃甃瘂UN 猃礁猃琂L / 球爃猃礂I.
Publisher Copyright:
© 2017 The Authors.
PY - 2017/11
Y1 - 2017/11
N2 - Objective: The aim of this research was to measure the effects of the ethyl acetate fraction of Kalanchoe pinnata (Lmk) Pers (EF-KP) on lupus arthritis mice. Methods: The research was performed by testing of CD123+ interferon-α (IFN-α+) dendritic cells and CD68+ interleukin 6 (IL-6+) macrophages as the main biomarkers using flow cytometry method, and then, the outcomes were directly observed in the joint’s tissue structure. The results of the research were analyzed using statistics. Results: The EF-KP reduced the relative percentages of CD123+IFN-α+ dendritic cells significantly (p<0.05) with the percentage of 32.95±8.25% (negative control); 23.28±9.31%* (EF-KP); and 22.98±10.39%* (positive control). It also reduces the relative percentages of CD68+IL-6+ macrophages but not significantly. Finally, the outcome to the grade of joint damage was scored using Pritzker method. The treated groups have one grade lower, and the joint spaces were narrower than the untreated group. Conclusion: The results show the ability of the active compounds in EF-KP, which are comparable to 0.042 mg/kg of quercetin, to inhibit the progress of lupus arthritis pathogenesis in mice. It might reveals the effectiveness of the EF-KP in human with lupus arthritis. However, the further clinical research is necessary.
AB - Objective: The aim of this research was to measure the effects of the ethyl acetate fraction of Kalanchoe pinnata (Lmk) Pers (EF-KP) on lupus arthritis mice. Methods: The research was performed by testing of CD123+ interferon-α (IFN-α+) dendritic cells and CD68+ interleukin 6 (IL-6+) macrophages as the main biomarkers using flow cytometry method, and then, the outcomes were directly observed in the joint’s tissue structure. The results of the research were analyzed using statistics. Results: The EF-KP reduced the relative percentages of CD123+IFN-α+ dendritic cells significantly (p<0.05) with the percentage of 32.95±8.25% (negative control); 23.28±9.31%* (EF-KP); and 22.98±10.39%* (positive control). It also reduces the relative percentages of CD68+IL-6+ macrophages but not significantly. Finally, the outcome to the grade of joint damage was scored using Pritzker method. The treated groups have one grade lower, and the joint spaces were narrower than the untreated group. Conclusion: The results show the ability of the active compounds in EF-KP, which are comparable to 0.042 mg/kg of quercetin, to inhibit the progress of lupus arthritis pathogenesis in mice. It might reveals the effectiveness of the EF-KP in human with lupus arthritis. However, the further clinical research is necessary.
KW - Cd123 interferon-α dendritic cells
KW - Cd68 interleukin 6 macrophages
KW - Flavonoids
KW - Kalanchoe pinnata (lmk) pers
KW - Lupus arthritis
UR - http://www.scopus.com/inward/record.url?scp=85034088683&partnerID=8YFLogxK
U2 - 10.22159/ajpcr.2017.v10i11.20766
DO - 10.22159/ajpcr.2017.v10i11.20766
M3 - Article
AN - SCOPUS:85034088683
SN - 0974-2441
VL - 10
SP - 199
EP - 203
JO - Asian Journal of Pharmaceutical and Clinical Research
JF - Asian Journal of Pharmaceutical and Clinical Research
IS - 11
ER -